Abbott Laboratories (ABT)
123.97
-2.18 (-1.73%)
NYSE · Last Trade: Nov 20th, 7:04 PM EST
Detailed Quote
| Previous Close | 126.15 |
|---|---|
| Open | 122.50 |
| Bid | 123.50 |
| Ask | 124.50 |
| Day's Range | 122.09 - 125.72 |
| 52 Week Range | 110.86 - 141.23 |
| Volume | 11,658,121 |
| Market Cap | 217.06B |
| PE Ratio (TTM) | 15.55 |
| EPS (TTM) | 8.0 |
| Dividend & Yield | 2.360 (1.90%) |
| 1 Month Average Volume | 6,012,648 |
Chart
About Abbott Laboratories (ABT)
Abbott Laboratories is a global healthcare company that specializes in the development of a wide range of medical devices, diagnostics, nutrition products, and pharmaceuticals. The company focuses on innovation to improve patient outcomes and enhance the quality of life for individuals worldwide. Abbott is known for its advancements in areas such as cardiovascular care, diabetes management, and nutrition science, providing essential tools and solutions that support healthcare professionals and patients in managing various health conditions. With a strong commitment to research and development, Abbott continually seeks to address unmet medical needs and contribute to the advancement of healthcare globally. Read More
News & Press Releases
On a big day for tech stocks, some other less well-known companies saw even larger moves.
Via The Motley Fool · November 20, 2025
The company received a buyout offer from Abbot Labs.
Via The Motley Fool · November 20, 2025
A healthcare giant covets the cancer screening leader's technology.
Via The Motley Fool · November 20, 2025
BALA CYNWYD, Pa., Nov. 20, 2025 (GLOBE NEWSWIRE) -- Law office of Brodsky & Smith announces that it is investigating potential claims against the Board of Directors of Exact Sciences Corporation (“Exact Sciences” or the “Company”) (Nasdaq – EXAS) for possible breaches of fiduciary duty and other violations of federal and state law in connection with the acquisition of the Company by Abbott (NYSE - ABT) for $105.00 per common share in cash, representing a total equity value of approximately $21 billion.
By Brodsky & Smith LLC · Via GlobeNewswire · November 20, 2025
Exact Sciences Stock Falls Premarket Despite Wall Street Calling For A Triple-Digit Abbott Takeoverstocktwits.com
Via Stocktwits · November 20, 2025
New York, NY – November 20, 2025 – UBS Group has adjusted its outlook on Medtronic plc (NYSE: MDT) stock, raising its price target to $102.00 from $95.00. This upward revision follows Medtronic's stronger-than-expected second-quarter fiscal 2026 earnings report, which showcased robust performance driven by key segments and innovative technology.
Via MarketMinute · November 20, 2025
Let's take a look at the S&P500 stocks that are experiencing notable price gaps in today's session on Thursday. Discover the gap up and gap down stocks in the S&P500 index.
Via Chartmill · November 20, 2025
Abbott will acquire Exact Sciences for $21 billion, adding Cologuard and expanding its diagnostics portfolio as analysts highlight growth and valuation momentum.
Via Benzinga · November 20, 2025
Under the deal, Exact Sciences shareholders will receive $105 per common share in cash.
Via Stocktwits · November 20, 2025
A strategic investor is reportedly in advanced talks to purchase the company.
Via The Motley Fool · November 19, 2025
Personal health and wellness is one of the many secular tailwinds for healthcare companies. But financial performance has lagged recently as players offloaded surplus COVID inventories in 2023 and 2024, a headwind for overall demand.
The result? Over the past six months, the industry’s 7.4% return has trailed the S&P 500 by 3.6 percentage points.
Via StockStory · November 19, 2025
Dividend stocks can strengthen your portfolio during any market environment.
Via The Motley Fool · November 15, 2025
These stocks pay income that investors can count on over the long run.
Via The Motley Fool · November 15, 2025
As the broader market concluded with a mixed performance on November 14, 2025, the S&P 500 Healthcare sector once again underscored its often-defensive nature, demonstrating resilience amidst an uncertain economic landscape. While specific real-time data for this future date is beyond current predictive capabilities, an analysis of the sector's
Via MarketMinute · November 14, 2025
The economic outlook for the U.S. Midwest has taken a concerning turn as the Chicago Federal Reserve's 7th District hiring expectations index reportedly plummeted to -40 in October 2025. This alarming figure represents the lowest reading for hiring expectations since the tumultuous year of 2020 and, excluding the pandemic
Via MarketMinute · November 10, 2025
These companies have already handsomely rewarded longtime shareholders, and it's not too late to join the party.
Via The Motley Fool · November 10, 2025
Recent third-quarter (Q3) 2025 corporate earnings have painted a complex yet largely positive picture for North American equity markets. While robust performances from key sectors, particularly technology, have propelled major U.S. and Canadian indices to new heights, a closer look reveals a landscape of mixed results, with individual company
Via MarketMinute · November 7, 2025
The financial markets are currently navigating a complex and often contradictory economic landscape, heavily influenced by a suite of critical indicators such as jobs data and the Purchasing Managers' Index (PMI). From late 2024 through November 2025, these barometers of economic health have signaled a period of deliberate rebalancing, characterized
Via MarketMinute · November 5, 2025
Looking back on medical devices & supplies - diversified stocks’ Q3 earnings, we examine this quarter’s best and worst performers, including Abbott Laboratories (NYSE:ABT) and its peers.
Via StockStory · November 3, 2025
AIs are hungry and growing more insatiable by the day. Will we be able to sustainably generate the power needed to feed the AI beast?
Via The Motley Fool · November 3, 2025
Via MarketBeat · November 1, 2025
Dexcom's solid third-quarter report was overshadowed Friday by its "surprisingly cautious" outlook, and Dexcom stock tumbled.
Via Investor's Business Daily · October 31, 2025
The company hasn't had a great year. Is it about to turn things around?
Via The Motley Fool · October 30, 2025
The third-quarter (Q3) 2025 earnings season has delivered a powerful jolt to global financial markets, propelling major U.S. indices to unprecedented record highs. A wave of surprisingly robust corporate earnings reports, coupled with growing optimism for further Federal Reserve interest rate cuts, has ignited a broad-based rally, signaling underlying
Via MarketMinute · October 28, 2025